With all eyes on Teva ahead of its planned reveal of a fresh strategy under new CEO Richard Francis at an investor day on 18 May, the Israeli firm has delivered first-quarter results that reflected a continued decline in North American generics sales even as the company enjoyed an uptick in other markets.
Meanwhile, Teva also offered an update on US launch plans for its recently-approved long-acting injectable risperidone product, Uzedy (see sidebar), as well as acknowledging a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?